A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study Of Oral PF-06651600 And PF-06700841 As Induction And Chronic Theraphy In Subjects With Moderate to Severe Ulcerative Colitis